Pressure Ulcer Treatment Strategies: Comparative Effectiveness
... Objectives. Pressure ulcers affect up to 3 million Americans and are a major source of morbidity, mortality, and health care cost. This review summarizes evidence comparing the effectiveness and safety of pressure ulcer treatment strategies. Data sources. Articles published between January 1, 1985, ...
... Objectives. Pressure ulcers affect up to 3 million Americans and are a major source of morbidity, mortality, and health care cost. This review summarizes evidence comparing the effectiveness and safety of pressure ulcer treatment strategies. Data sources. Articles published between January 1, 1985, ...
Buprenorphine Bibliography - ATTC Addiction Technology Transfer
... Abstract: (1) Three years after high-dose buprenorphine preparations were first marketed in France, we examine their use as replacement therapy for heroin addiction. (2) Various surveys of community pharmacists have shown that the prescribing and dispensing conditions are feasible in the routine amb ...
... Abstract: (1) Three years after high-dose buprenorphine preparations were first marketed in France, we examine their use as replacement therapy for heroin addiction. (2) Various surveys of community pharmacists have shown that the prescribing and dispensing conditions are feasible in the routine amb ...
Theophylline
... could limit the need for blood samples in treatment with theophylline. The place in therapy of theophylline in children is and should be limited, which is also reflected in international and national guidelines. No new efficacy or safety information has emerged from the submitted studies, but it is ...
... could limit the need for blood samples in treatment with theophylline. The place in therapy of theophylline in children is and should be limited, which is also reflected in international and national guidelines. No new efficacy or safety information has emerged from the submitted studies, but it is ...
Second-Generation Antidepressants in the Pharmacologic Treatment of Adult
... International Pharmaceutical Abstracts up to January 2011. Review Methods. Two people independently reviewed the literature, abstracted data, and rated the risk of bias. If data were sufficient, we conducted meta-analyses of head-to-head trials of the relative benefit of response to treatment. In ad ...
... International Pharmaceutical Abstracts up to January 2011. Review Methods. Two people independently reviewed the literature, abstracted data, and rated the risk of bias. If data were sufficient, we conducted meta-analyses of head-to-head trials of the relative benefit of response to treatment. In ad ...
Clinical effectiveness and cost-effectiveness of foam sclerotherapy
... foam (EQ-5D, p = 0.004). There were fewer procedural complications in the EVLA group (1%) than after foam (7%) and surgery (8%) (p < 0.001). Participants returned to a wide range of behaviours more quickly following foam or EVLA than following surgery (p < 0.05). There were no differences in VCSS be ...
... foam (EQ-5D, p = 0.004). There were fewer procedural complications in the EVLA group (1%) than after foam (7%) and surgery (8%) (p < 0.001). Participants returned to a wide range of behaviours more quickly following foam or EVLA than following surgery (p < 0.05). There were no differences in VCSS be ...
Table 3: Brain imaging studies of patients with hypertension, without
... 6. Over 2-yr follow-up, change in total WMH fraction was greater in subjects with HTN compared with subjects without HTN. 7. Over 2-yr follow-up, the deep WMH fraction increased in subjects with HTN but not in subjects without HTN. Guo et al. ...
... 6. Over 2-yr follow-up, change in total WMH fraction was greater in subjects with HTN compared with subjects without HTN. 7. Over 2-yr follow-up, the deep WMH fraction increased in subjects with HTN but not in subjects without HTN. Guo et al. ...
Allergic Rhinitis and its Impact on Asthma (ARIA)
... J.B., S.B., G.W.C., R.GvW., H.J.S. and T.Z. are members of GA2LEN (Global Allergy and Asthma European Network) supported by European Commission Framework Programme grant FOOD-CT2004-506378. Address for correspondence: Holger J Schünemann, MD, PhD, MSc Chair, Department of Clinical Epidemiology & Bio ...
... J.B., S.B., G.W.C., R.GvW., H.J.S. and T.Z. are members of GA2LEN (Global Allergy and Asthma European Network) supported by European Commission Framework Programme grant FOOD-CT2004-506378. Address for correspondence: Holger J Schünemann, MD, PhD, MSc Chair, Department of Clinical Epidemiology & Bio ...
http://www.cadth.ca/media/pdf/TR0004_RRMS_ScienceReport_e.pdf
... report contains a comprehensive review of the existing public literature, studies, materials, and other information and documentation (collectively the “source documentation”) available to CADTH at the time of report preparation. The information in this report is intended to help Canadian health car ...
... report contains a comprehensive review of the existing public literature, studies, materials, and other information and documentation (collectively the “source documentation”) available to CADTH at the time of report preparation. The information in this report is intended to help Canadian health car ...
Evidence Reports of Kampo Treatment 2013: 402 Randomized
... collecting randomized controlled trials (RCTs) of Kampo medicines in Japan, and then prepared and published structured abstracts (SAs) on the Japan Society for Oriental Medicine (JSOM) website as Kampo Chiryo Ebidensu Repoto (Evidence Reports of Kampo Treatment: EKAT). As indicated in the History of ...
... collecting randomized controlled trials (RCTs) of Kampo medicines in Japan, and then prepared and published structured abstracts (SAs) on the Japan Society for Oriental Medicine (JSOM) website as Kampo Chiryo Ebidensu Repoto (Evidence Reports of Kampo Treatment: EKAT). As indicated in the History of ...
Osteoarthritis — Care and management in adults
... 8.1.10 Health economic evidence statements ................................................................ 140 8.1.11 From evidence to recommendations ................................................................... 144 ...
... 8.1.10 Health economic evidence statements ................................................................ 140 8.1.11 From evidence to recommendations ................................................................... 144 ...
Clinical Study Report
... Medications are administered in the following fixed sequence: 1. ICS (if regular posology) and leukotriene modifier (LTRA) (if applicable), 2. trial medication from assigned MDI, 3. trial medication from assigned Respimat®. Patient’s ICS should be administered without change in posology (bid/qd; am/ ...
... Medications are administered in the following fixed sequence: 1. ICS (if regular posology) and leukotriene modifier (LTRA) (if applicable), 2. trial medication from assigned MDI, 3. trial medication from assigned Respimat®. Patient’s ICS should be administered without change in posology (bid/qd; am/ ...
Module 2.5 Clinical Overview
... viral enzyme, which catalyzes two key steps in the HIV life cycle and is responsible for insertion of the viral genome into the deoxyribonucleic acid (DNA) of the host cell. Since genome integration is a vital step in retroviral replication, it is an attractive target for HIV therapy. Dolutegravir ( ...
... viral enzyme, which catalyzes two key steps in the HIV life cycle and is responsible for insertion of the viral genome into the deoxyribonucleic acid (DNA) of the host cell. Since genome integration is a vital step in retroviral replication, it is an attractive target for HIV therapy. Dolutegravir ( ...
H Headaches in Children and Adolescents Donald W. Lewis, MD Clinical Evaluation
... practitioner as to which patients warrant further diagnostic testing, as each of these patterns suggests its own specific differential diagnosis, which in turn, guides the need and urgency for ancillary studies. For example, an explosive, hyperacute headache in an older adolescent, that begins sudde ...
... practitioner as to which patients warrant further diagnostic testing, as each of these patterns suggests its own specific differential diagnosis, which in turn, guides the need and urgency for ancillary studies. For example, an explosive, hyperacute headache in an older adolescent, that begins sudde ...
Treatments for Atopic Eczema
... analysis first developed by Thomas Bayes, which tests the likelihood of something occuring in the light of prior knowledge and belief about what is likely to happen. This is different from traditional ‘frequentist’ statistics, which seeks to disprove the null hypothesis of no difference between the ...
... analysis first developed by Thomas Bayes, which tests the likelihood of something occuring in the light of prior knowledge and belief about what is likely to happen. This is different from traditional ‘frequentist’ statistics, which seeks to disprove the null hypothesis of no difference between the ...
Diagnosis and management of headache in adults.
... and include any head pain of infectious, neoplastic, vascular, or drug-induced origin.5 Migraine is the most common severe form of primary headache affecting about six million people in the UK in the age range 16-65, and can cause significant disability.6 The World Health Organisation (WHO) ranks mi ...
... and include any head pain of infectious, neoplastic, vascular, or drug-induced origin.5 Migraine is the most common severe form of primary headache affecting about six million people in the UK in the age range 16-65, and can cause significant disability.6 The World Health Organisation (WHO) ranks mi ...
The PROMUS® Everolimus Eluting Coronary Stent System
... The PROMUS® (2.25 – 4.0 mm) Everolimus-Eluting Coronary Stent System (hereinafter referred to as PROMUS EECSS or PROMUS stent system) is a private-labeled XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V EECSS or XIENCE V stent system) manufactured by Abbott and distributed by Boston Sci ...
... The PROMUS® (2.25 – 4.0 mm) Everolimus-Eluting Coronary Stent System (hereinafter referred to as PROMUS EECSS or PROMUS stent system) is a private-labeled XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V EECSS or XIENCE V stent system) manufactured by Abbott and distributed by Boston Sci ...
Boston Scientific Inc. PROMUSâ„¢ Everolimus Eluting Coronary
... The PROMUS® (2.25 – 4.0 mm) Everolimus-Eluting Coronary Stent System (hereinafter referred to as PROMUS EECSS or PROMUS stent system) is a private-labeled XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V EECSS or XIENCE V stent system) manufactured by Abbott and distributed by Boston Sci ...
... The PROMUS® (2.25 – 4.0 mm) Everolimus-Eluting Coronary Stent System (hereinafter referred to as PROMUS EECSS or PROMUS stent system) is a private-labeled XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V EECSS or XIENCE V stent system) manufactured by Abbott and distributed by Boston Sci ...
report released today
... 21. There may be variation in the results produced by different RCTs, particularly if there are many trials with low statistical power, that is, small trials with low numbers of participants. When trials produce varying results, proponents of both sides of an argument can “cherry-pick” data to suppo ...
... 21. There may be variation in the results produced by different RCTs, particularly if there are many trials with low statistical power, that is, small trials with low numbers of participants. When trials produce varying results, proponents of both sides of an argument can “cherry-pick” data to suppo ...
Interventions for impetigo (Review)
... years ago as an alternative for antibiotic treatment, but is now said to be no more effective than placebo (Dagan 1992). Guidelines and treatment advice often do not mention topical cleansing as a treatment because frequently the main concern is preventing the spread of the infection to other childr ...
... years ago as an alternative for antibiotic treatment, but is now said to be no more effective than placebo (Dagan 1992). Guidelines and treatment advice often do not mention topical cleansing as a treatment because frequently the main concern is preventing the spread of the infection to other childr ...
Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for
... he Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘ ...
... he Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘ ...
A COMPARISON OF PHYSIOTHERAPY AND RICE SELF
... Randomisation of participants into RICE and physiotherapy groups .............................................. 59 Participant recruitment .................................................................................................................... 60 EQUIPMENT ............................... ...
... Randomisation of participants into RICE and physiotherapy groups .............................................. 59 Participant recruitment .................................................................................................................... 60 EQUIPMENT ............................... ...
Relvar Ellipta : EPAR - Product Information - EMA
... If symptoms arise in the period between doses, an inhaled, short-acting beta 2 -agonist should be taken for immediate relief. A starting dose of Relvar Ellipta 92/22 micrograms should be considered for adults and adolescents 12 years and over who require a low to mid dose of inhaled corticosteroid i ...
... If symptoms arise in the period between doses, an inhaled, short-acting beta 2 -agonist should be taken for immediate relief. A starting dose of Relvar Ellipta 92/22 micrograms should be considered for adults and adolescents 12 years and over who require a low to mid dose of inhaled corticosteroid i ...
Australian Public Assessment Report for Dasatinib Proprietary Product Name: Sprycel
... estimated covariate effect of treatment status (first line imatinib naive and second line imatinib experienced) on the parameters of interest (apparent clearance [CL/F) and apparent distribution volume of the central compartment [VC/F]). Third, the final model was obtained by eliminating those covar ...
... estimated covariate effect of treatment status (first line imatinib naive and second line imatinib experienced) on the parameters of interest (apparent clearance [CL/F) and apparent distribution volume of the central compartment [VC/F]). Third, the final model was obtained by eliminating those covar ...
1 ——— CONTRAINDICATIONS ——— Hypersensitivity to the
... with TRETTEN® and non-proteolytically activated recombinant FXIII at a dose of 1670 IU/kg, i.e., 48 times the recommended human dose of 35 IU/kg. In a monkey cardiovascular safety pharmacology model evaluating the combination of excessive doses of TRETTEN® (585 IU/kg, 17 times the expected human dos ...
... with TRETTEN® and non-proteolytically activated recombinant FXIII at a dose of 1670 IU/kg, i.e., 48 times the recommended human dose of 35 IU/kg. In a monkey cardiovascular safety pharmacology model evaluating the combination of excessive doses of TRETTEN® (585 IU/kg, 17 times the expected human dos ...
March 2009 ProArgin Sp Issue - the American Journal of Dentistry
... measure dentin hypersensitivity.20 The tooth which is sensitive is isolated and a blast of air (approximately 40 psi) is applied to the exposed dentin surface. The response of the subject to the air blast stimulus is assigned using an analog scale, such as the commonly used “Schiff” scale. A value o ...
... measure dentin hypersensitivity.20 The tooth which is sensitive is isolated and a blast of air (approximately 40 psi) is applied to the exposed dentin surface. The response of the subject to the air blast stimulus is assigned using an analog scale, such as the commonly used “Schiff” scale. A value o ...
Placebo-controlled study
Placebo-controlled studies are a way of testing a medical therapy in which, in addition to a group of subjects that receives the treatment to be evaluated, a separate control group receives a sham ""placebo"" treatment which is specifically designed to have no real effect. Placebos are most commonly used in blinded trials, where subjects do not know whether they are receiving real or placebo treatment. Often, there is also a further ""natural history"" group that does not receive any treatment at all.The purpose of the placebo group is to account for the placebo effect, that is, effects from treatment that do not depend on the treatment itself. Such factors include knowing one is receiving a treatment, attention from health care professionals, and the expectations of a treatment's effectiveness by those running the research study. Without a placebo group to compare against, it is not possible to know whether the treatment itself had any effect.Patients frequently show improvement even when given a sham or ""fake"" treatment. Such intentionally inert placebo treatments can take many forms, such as a pill containing only sugar, a surgery where nothing efficacious is actually done (just an incision and sometimes some minor touching or handling of the underlying structures), or a medical device (such as an ultrasound machine) that is not actually turned on. Also, due to the body's natural healing ability and statistical effects such as regression to the mean, many patients will get better even when given no treatment at all. Thus, the relevant question when assessing a treatment is not ""does the treatment work?"" but ""does the treatment work better than a placebo treatment, or no treatment at all?"" As one early clinical trial researcher wrote, ""the first object of a therapeutic trial is to discover whether the patients who receive the treatment under investigation are cured more rapidly, more completely or more frequently, than they would have been without it.""p.195 More broadly, the aim of a clinical trial is to determine what treatments, delivered in what circumstances, to which patients, in what conditions, are the most effective.Therefore, the use of placebos is a standard control component of most clinical trials, which attempt to make some sort of quantitative assessment of the efficacy of medicinal drugs or treatments. Such a test or clinical trial is called a placebo-controlled study, and its control is of the negative type. A study whose control is a previously tested treatment, rather than no treatment, is called a positive-control study, because its control is of the positive type.Government regulatory agencies approve new drugs only after tests establish not only that patients respond to them, but also that their effect is greater than that of a placebo (by way of affecting more patients, by affecting responders more strongly, or both). As a result, ""placebo-controlled studies often are designed in such a way that disadvantages the placebo condition"".